

# Anu Haveri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9648596/anu-haveri-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14 papers	248 citations	4 h-index	15 g-index
17 ext. papers	379 ext. citations	7 avg, IF	3.16 L-index

#	Paper	IF	Citations
14	Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.. <i>Microbiology Spectrum</i> , <b>2022</b> , e0225221	8.9	1
13	Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3 mRNA vaccination in health care workers and elderly subjects.. <i>European Journal of Immunology</i> , <b>2022</b> ,	6.1	3
12	A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. <i>Microbiology Spectrum</i> , <b>2021</b> , e0113121	8.9	3
11	Clinical validation of automated and rapid mariPOC SARS-CoV-2 antigen test. <i>Scientific Reports</i> , <b>2021</b> , 11, 20363	4.9	2
10	A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 218-228	7	10
9	Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients - a prospective observational study. <i>Infectious Diseases</i> , <b>2021</b> , 53, 111-121	3.1	20
8	Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines. <i>Vaccine</i> , <b>2021</b> , 39, 402-411	4.1	2
7	Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. <i>European Journal of Immunology</i> , <b>2021</b> ,	6.1	22
6	Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	171
5	Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses. <i>Vaccine</i> , <b>2019</b> , 37, 2731-2740	4.1	2
4	Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults		3
3	High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020		1
2	Persistence of neutralizing antibodies a year after SARS-CoV-2 infection		3
1	Analytical and clinical evaluation of antibody tests for SARS-CoV-2 serosurveillance studies used in Finland in 2020		3